Showing results (11-20 of 45) with videos related to
Sort By:
Pageof 5
Biochemical Pharmacology|September 2, 2003
Inhibition of markers of hepatic stellate cell activation by the hormone relaxinRobert G Bennett, Kusum K Kharbanda, Dean J TumaWorld Journal of Gastroenterology|June 28, 2017
Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosisRobert G Bennett, Ronda L Simpson, Frederick G HamelExpert Opinion on Therapeutic Targets|June 15, 2024
Therapeutic perspectives on PDE4B inhibition in adipose tissue dysfunction and chronic liver injuryDalton W Staller, Robert G Bennett, Ram I MahatoDiabetes|August 28, 2003
An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell culturesRobert G Bennett, Frederick G Hamel, William C DuckworthAnnals of the New York Academy of Sciences|May 7, 2009
Degradation of relaxin family peptides by insulin-degrading enzymeRobert G Bennett, Dean G Heimann, Frederick G HamelAnnals of the New York Academy of Sciences|May 7, 2009
Relaxin reduces fibrosis in models of progressive and established hepatic fibrosisRobert G Bennett, Dean G Heimann, Dean J TumaEndocrinology|May 15, 2003
In vitro inhibition of insulin-degrading enzyme by long-chain fatty acids and their coenzyme A thioestersFrederick G Hamel, Jennifer L Upward, Robert G BennettCurrent Opinion in Clinical Nutrition and Metabolic Care|April 13, 2004
Control of proteolysis: hormones, nutrients, and the changing role of the proteasomeFrederick G Hamel, Janet Fawcett, Robert G Bennett, et al.Plos One|March 31, 2011
Redox regulation of insulin degradation by insulin-degrading enzymeCrystal M Cordes, Robert G Bennett, Gerri L Siford, et al.Biology|July 8, 2020
A Selective PPARγ Modulator Reduces Hepatic FibrosisBenita L McVicker, Frederick G Hamel, Ronda L Simpson, et al.Pageof 5